Atherosclerotic Cardiovascular Disease
📧 Sign up to get email alerts when something new happens for Atherosclerotic Cardiovascular Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-02-08FDA Approved: ATORVASTATIN CALCIUM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the first original application for atorvastatin calcium as a generic product from Novadoz Pharmaceuticals LLC.
-
CLINICAL_TRIALS research · 2019-02-01Clinical Trial Update: Mind Our Heart Study [NA]
Clinical trial update for the Mind Our Heart Study (sponsor: Catharina Ziekenhuis Eindhoven) listing Peripheral Arterial Disease, Heart Fail…
-
FDA approval · 2018-12-31FDA Approved: SIMVASTATIN — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for simvastatin from NorthStar Rx LLC, updating the approved generic product's labeling/manufacturin…
-
FDA approval · 2018-12-31FDA Approved: SIMVASTATIN — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for SIMVASTATIN from Accord Healthcare, Inc., updating the approved product. This action concerns a …
-
FDA approval · 2018-12-21FDA Approved: ATORVASTATIN CALCIUM — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' atorvastatin calcium as an original generic application, authorizing a new generic version of atorvast…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-11-20FDA Approved: ATORVASTATIN CALCIUM — Original Application (Zydus Lifesciences Limited)
FDA approved the original application for atorvastatin calcium from Zydus Lifesciences Limited, granting generic approval for lowering chole…
-
FDA approval · 2018-08-22FDA Approved: PRALUENT — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved a supplemental application for PRALUENT (alirocumab) submitted by Regeneron Pharmaceuticals, Inc.
-
FDA approval · 2018-06-18FDA Approved: ATORVASTATIN CALCIUM — Original Application (Rising Pharma Holdings, Inc.)
FDA approved Rising Pharma's generic atorvastatin calcium (original ANDA) for lowering cholesterol and reducing cardiovascular risk.
-
FDA approval · 2018-06-07FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Quallent)
FDA approved a supplemental application for atorvastatin calcium from Quallent, authorizing continued approval of this generic statin produc…
-
FDA approval · 2018-05-21FDA Approved: EZETIMIBE — Supplemental Application (Ascend Laboratories, LLC)
FDA has approved a supplemental application for ezetimibe from Ascend Laboratories, LLC, authorizing continued marketing under the ANDA.
-
CLINICAL_TRIALS trial_result · 2018-05-04Clinical Trial Update: REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification [Phase 3]
Phase 3 trial REVEAL evaluated the lipid-modifying effects of anacetrapib in patients with atherosclerotic cardiovascular disease; results w…
-
FDA approval · 2018-04-13FDA Approved: PRAVASTATIN SODIUM — Original Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma's pravastatin sodium as an original ANDA, authorizing a generic version of pravastatin for lowering cholesterol. …
-
FDA approval · 2018-03-30FDA Approved: ATORVASTATIN CALCIUM — Original Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare's atorvastatin calcium as an original application (ANDA) for a generic atorvastatin calcium product.
-
FDA approval · 2018-02-28FDA Approved: ZOCOR — Supplemental Application (Organon LLC)
FDA approved a supplemental application for ZOCOR (simvastatin) submitted by Organon LLC. The action commonly updates labeling, indications,…
-
FDA approval · 2017-12-22FDA Approved: EZETIMIBE AND SIMVASTATIN — Original Application (Ascend Laboratories, LLC)
FDA approved an original application for a fixed-dose combination of ezetimibe and simvastatin by Ascend Laboratories, LLC.
-
FDA approval · 2017-11-21FDA Approved: EZETIMIBE AND SIMVASTATIN — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal's original application for a generic fixed-dose combination of ezetimibe and simvastatin (EZETIMIBE AND SIMVASTATIN). Th…
-
CLINICAL_TRIALS research · 2017-11-17Clinical Trial Update: The Effect of Psyllium Fibre on LDL-C, Non-HDL-C, and Apolioprotein-B: A Systematic Review and Meta-analysis
A systematic review and meta-analysis evaluates how psyllium fiber affects LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH [NA]
Update on the Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH); the trial status is completed and involves patients with …
-
FDA approval · 2017-09-11FDA Approved: GEMFIBROZIL — Supplemental Application (Cadila Pharmaceuticals Limited)
The FDA approved a supplemental application for Gemfibrozil filed by Cadila Pharmaceuticals Limited.
-
FDA label_change · 2017-08-04FDA Approved: LESCOL XL — Supplemental Application (Sandoz Inc)
FDA is reviewing a supplemental application for LESCOL XL (fluvastatin sodium) from Sandoz Inc., likely involving changes to the product lab…
-
FDA label_change · 2017-07-27FDA Approved: PRALUENT — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved a supplemental application for PRALUENT (alirocumab) from Regeneron Pharmaceuticals to update the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2017-07-24Clinical Trial Update: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events [Phase 3]
A Phase 3 randomized trial of bococizumab in adults with hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events has completed…
-
FDA approval · 2017-07-11FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin Pharmaceuticals' supplemental application for pravastatin sodium (a generic statin product).
-
FDA approval · 2017-06-30FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (CIPLA USA INC.)
FDA approved a supplemental application for pravastatin sodium submitted by Cipla USA Inc., indicating an approved modification to the gener…
-
FDA approval · 2017-06-23FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for the combination drug amlodipine and atorvastatin. The product is intend…